Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14133956 | 0.92 | KIF11 (0.45) | KIF11ACHEMAPTPARP1BRAF | |
| SCHEMBL14133169 | 0.79 | KIF11 (0.56) | KIF11ACHEMAPTPARP1CHUK | |
| SCHEMBL14053792 | 0.79 | KIF11 (0.56) | KIF11ACHEMAPTPARP1CHUK | |
| SCHEMBL23391734 | 0.77 | TBXAS1 (0.52) | KIF11ACHEMAPTPARP1ROCK2 | |
| SCHEMBL31104422 | 0.77 | TBXAS1 (0.52) | KIF11ACHEMAPTPARP1ROCK2 | |
| SCHEMBL14133908 | 0.77 | KIF11 (0.54) | KIF11ACHEMAPTPARP1CHUK | |
| SCHEMBL14053477 | 0.77 | KIF11 (0.54) | KIF11ACHEMAPTPARP1CHUK | |
| SCHEMBL20652942 | 0.76 | KDM4E (0.50) | KIF11ACHEMAPTPARP1ROCK2 | |
| SCHEMBL20652671 | 0.76 | ACHE (0.51) | KIF11ACHEMAPTPARP1CHUK | |
| SCHEMBL20652663 | 0.73 | ROCK2 (0.50) | KIF11ACHEMAPTPARP1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | claimed |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | SLC18A3, TSPO, CHAT | KIF11 3323/4885ACHE 5/4885MAPT 36/4885 |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SLC18A3, TSPO, CHAT | KIF11 3323/4885ACHE 5/4885MAPT 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.